FGAM
XERS icon

Financial Gravity Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History

Financial Gravity Asset Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3
Closed – – 1794
2023
Q2 		$0 Buy
+3
New +$8 ﹤0.01% 1778
2023
Q1 		– Sell
-1
Closed – – 1695
2022
Q4 		$0 Buy
+1
New +$1 ﹤0.01% 1542

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Financial Gravity Asset Management's XERS Position: Q3 2023 in Review

Financial Gravity Asset Management sold out of Xeris Biopharma Holdings (XERS) in Q3 2023, closing a stake of 3 shares.

Financial Gravity Asset Management first reported a position in XERS in Q4 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2023. 110 funds tracked by Wall St. Rank hold XERS as of Q3 2023.

  • Financial Gravity Asset Management reported no remaining Xeris Biopharma Holdings position as of Q3 2023 after selling out during the quarter.
  • Financial Gravity Asset Management sold 3 Xeris Biopharma Holdings shares in Q3 2023.
  • Financial Gravity Asset Management first reported a position in Xeris Biopharma Holdings in Q4 2022 and held it in 2 quarters.
  • Financial Gravity Asset Management's Xeris Biopharma Holdings position peaked at $0 in Q2 2023.
  • 110 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2023.

Based on Financial Gravity Asset Management's 13F filing for Q3 2023, filed 16 Nov 2023.